Samsung Bioepis Email Format
Pharmaceutical Manufacturing인천광역시, South Korea1001-5000 Employees
Samsung Bioepis is a biopharmaceutical company in the pharmaceutical manufacturing industry established in 2012 and based in Yeonsu District, Incheon, South Korea (postal code 21987). It develops and commercializes biosimilars and maintains a broad pipeline across immunology, oncology, ophthalmology, hematology, nephrology, and endocrinology. The company engages in global partnerships and market activity in Europe and Japan, including the May 2026 launch of OPUVIZ aflibercept 40 mg/mL vial in Europe and the May 2026 launch of Ustekinumab BS 45 mg syringe for subcutaneous injection in Japan through Nipro. Samsung Bioepis has pursued open-innovation and strategic collaborations, such as a 2025–2026 partnership with Nipro for development and commercialization of multiple biosimilar candidates in Japan, and an MoU with ATLATL Innovation Center to accelerate early-stage biotech innovation in the Asia-Pacific region. The company employs between 1,001 and 5,000 people and maintains its online presence at www.samsungbioepis.com.